Central imidazoline receptors as a target for centrally acting antihypertensive drugs
- 33 Downloads
Imidazoline (I1)-receptors in the central nervous system play a role in the central regulation of blood pressure and heart rate. Stimulation of these receptors in the rostral ventrolateral medulla induces peripheral sympathoinhibition, and hence a reduction of elevated blood pressure. The imidazoline derivatives moxonidine and rilmenidine are moderately selective I1 receptor stimulants which have been introduced as centrally acting antihypertensives. Since they have little affinity for α2-adrenoceptors, they may be expected to cause less sedation and dry mouth than the α2-adrenoceptor agonists clonidine and methyldopa. The concept of I1 receptors and their agonists therefore offers the possibility to develop centrally acting antihypertensives with a more favourable profile of adverse reactions than the classical α2-adrenoceptor stimulants such as clonidine and methyldopa.
KeywordsAntihypertensive agents Clonidine Moxonidine Receptors, adrenergic, alpha-2 Receptors, imidazoline Rilmenidine
Unable to display preview. Download preview PDF.
- 1.Van Zwieten PA, Thoolen MJMC, Timmermans PBMWM. The hypotensive activity and side-effects of methyldopa, clonidine and guanfacine. Hypertension 1984;6 Suppl 11: 28–33.Google Scholar
- 2.Van Zwieten PA, Thoolen MJMC, Timmermans PBMWM. The pharmacological base of the hypotensive activity and side-effects of α-methyl-DOPA, clonidine and guanfacine. Hypertension 1984;6:11–28.Google Scholar
- 7.Henning M. α-methyl-DOPA and related compounds. In: Van Zwieten PA, editor. Handbook of hypertension. Vol. 3. Pharmacology of antihypertensive drugs. Amsterdam: Elsevier, 1984:154–93.Google Scholar
- 10.Haxhiu MA, Dreshaj I, Schäfer SG, Ernsberger P. Selective antihypertensive action of moxonidine is mediated mainly by I1-imidazoline receptors in the rostral ventrolateral medulla. J Cardiovasc Pharmacol 1994;24 Suppl 1:S1–8.Google Scholar
- 19.Ollivier JP, Christen MO. I1-imidazoline-receptor agonists in the treatment of hypertension: an appraisal of clinical experience. J Cardiovasc Pharmacol 1994;24 Suppl 1:S39–48.Google Scholar
- 21.Ernsberger P, Westbrooks KL, Christen MO, Schäfer SG. A second generation of centrally acting antihypertensives acts on putative I1-imidazoline receptors. J Cardiovasc Pharmacol 1992;20 Suppl 4:S1–10.Google Scholar
- 22.Chrisp P, Faulds D. Moxonidine. Drugs 1992;44:993–1012.Google Scholar
- 23.Dollery CT. Rilmenidine in mild to moderate hypertension. A double-blind, randomised, parallel group multicenter comparison with methyldopa in 157 patients. Curr Ther Res 1990;47:194–221.Google Scholar
- 25.Parini A, Bousquet P. From α2-adrenoceptors to imidazoline preferring receptors. Fundam Clin Pharmacol 1992;6 Suppl 1:1S-63S.Google Scholar
- 28.Kaan EC, Brückner R, Frohly P, Tulp M, Schäfer SG, Zügler D. Effects of agmatine and moxonidine on glucose metabolism. Cardiovasc Risk Factors 1995. In press.Google Scholar